title: True versus immunoreactive angiotensin II in human plasma.
abstract: To measure specifically angiotensin-(1-8)octapeptide, peptides were extracted from 2 ml of plasma by reversible adsorption to bonded-phase silica. The angiotensin-(1-8)octapeptide was then isolated by isocratic reversed-phase high-performance liquid chromatography and quantified by radioimmunoassay. The extraction recovery of 125I-angiotensin II added to 2 ml of plasma was 99 +/- 2% (mean +/- SD). The overall recovery of 5, 10, and 20 fmol unlabeled angiotensin II added to 1 ml of plasma was 80 +/- 10%. The coefficient of variation for within-assay precision was 0.06 and for between-assay precision 0.13. The detection limit was 0.4 fmol/ml. Buffer and plasma blanks were below the detection limit. Normal subjects on a free diet in supine position averaged 4.2 +/- 1.7 fmol/ml angiotensin-(1-8)octapeptide. Furosemide (40 mg p.o.) and standing increased these values to 22 +/- 7.6 fmol/ml. In four volunteers, immunoreactive "angiotensin II" (more or less angiotensin-like material) was measured serially before and after converting-enzyme inhibition (Hoe 498) with conventional Dowex extraction. At peak inhibition, plasma immunoreactive "angiotensin II" levels decreased by only 44%. In contrast, angiotensin-(1-8)-octapeptide isolated by high-performance liquid chromatography completely disappeared. In hypertensive patients receiving long-term treatment with enalapril, plasma levels of angiotensin-(1-8)octapeptide fell from 2.7 +/- 0.9 to 0.9 +/- 0.3 fmol/ml (mean +/- SEM) 2 hours after the morning dose, whereas levels of immunoreactive "angiotensin II" were not significantly changed. We found that this sensitive method specifically measured angiotensin-(1-8)octapeptide and demonstrated that true angiotensin II virtually disappears during converting-enzyme inhibition.
authors.forename: J
authors.initials: J
authors.lastname: Nussberger
authors.forename: D B
authors.initials: DB
authors.lastname: Brunner
authors.forename: B
authors.initials: B
authors.lastname: Waeber
authors.forename: H R
authors.initials: HR
authors.lastname: Brunner
mesh_terms: D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000097:blood* / Q000276:immunology; D000937:Antigen-Antibody Reactions; D001643:Bridged Bicyclo Compounds / Q000494:pharmacology; D002851:Chromatography, High Pressure Liquid; D003429:Cross Reactions; D004151:Dipeptides / Q000627:therapeutic use; D004656:Enalapril; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000494:pharmacology; D011863:Radioimmunoassay; D017257:Ramipril; D012084:Renin-Angiotensin System; D013722:Teprotide
chemical_list: D001643:Bridged Bicyclo Compounds; D004151:Dipeptides; D009842:Oligopeptides; D000804:Angiotensin II; D004656:Enalapril; D013722:Teprotide; D017257:Ramipril